American Journal of Clinical Dermatology

, Volume 17, Issue 6, pp 625–634 | Cite as

Primary and Secondary Chemoprevention of Malignant Melanoma

  • Jessica Mounessa
  • Talayesa Buntinx-Krieg
  • Rosie Qin
  • Cory A. Dunnick
  • Robert P. Dellavalle
Review Article

Abstract

The incidence of malignant melanoma (MM) continues to rise in the United States. While sun protection and full body skin examinations remain the mainstay of preventative care, chemoprevention of the deadly disease has become an increasingly popular field of study. In this focused review, we discuss current findings and analyze the risks and benefits of various agents investigated for the primary and secondary chemoprevention of MM. Such agents include topical retinoids, vitamins, and supplements, Polypodium leucotomas extracts, non-steroidal anti-inflammatory agents (NSAIDs), statins, sunscreens, and field therapy with topical imiquimod for primary and secondary chemoprevention. We further identify a need for expanded high quality human research on the topic.

References

  1. 1.
    Society AC. Cancer Facts & Figures 2015. 2015.Google Scholar
  2. 2.
    Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Bethesda: National Cancer Institute 2012 December 23, 2015.Google Scholar
  3. 3.
    Society AC. Melanoma Skin Cancer; 2015.Google Scholar
  4. 4.
    Constantinou M. Melanoma Genomics and Immunotherapy. R I Med J (2013). 2015;98(11):31–4.Google Scholar
  5. 5.
    Skin Cancer Prevention Progress Report 2016. Atlanta: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2016.Google Scholar
  6. 6.
    Hong WK, Spitz MR, Lippman SM. Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. J Clin Oncol. 2000;18(21 Suppl):9s–18s.PubMedGoogle Scholar
  7. 7.
    Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002;41(3):269–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol. 2006;54(6):933–46 (quiz 47–50).Google Scholar
  9. 9.
    Alizadeh F, Bolhassani A, Khavari A, Bathaie SZ, Naji T, Bidgoli SA. Retinoids and their biological effects against cancer. Int Immunopharmacol. 2014;18(1):43–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Lotan R, Giotta G, Nork E, Nicolson GL. Characterization of the inhibitory effects of retinoids on the in vitro growth of two malignant murine melanomas. J Natl Cancer Inst. 1978;60(5):1035–41.PubMedGoogle Scholar
  11. 11.
    Lotan R. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res. 1979;39(3):1014–9.PubMedGoogle Scholar
  12. 12.
    Levine N, Meyskens FL. Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. Lancet (London, England). 1980;2(8188):224–6.Google Scholar
  13. 13.
    Meyskens FL Jr, Edwards L, Levine NS. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol. 1986;15(4 Pt 2):822–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Edwards L, Jaffe P. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. Arch Dermatol. 1990;126(4):494–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Halpern AC, Schuchter LM, Elder DE, Dt Guerry, Elenitsas R, Trock B, et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol. 1994;12(5):1028–35.PubMedGoogle Scholar
  16. 16.
    Stam-Posthuma JJ, Vink J, le Cessie S, Bruijn JA, Bergman W, Pavel S. Effect of topical tretinoin under occlusion on atypical naevi. Melanoma Res. 1998;8(6):539–48.CrossRefPubMedGoogle Scholar
  17. 17.
    Bettoli V, Zauli S, Virgili A. Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how. J Dermatol Treat. 2013;24(3):235–7.CrossRefGoogle Scholar
  18. 18.
    Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618–26.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, et al. A phase 2 randomised controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol. 2016. doi:10.1111/bjd.14662.
  20. 20.
    Thompson BC, Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes. Exp Dermatol. 2014;23(7):509–11.CrossRefPubMedGoogle Scholar
  21. 21.
    Horvath A, Alvarado F, Szocs J, de Alvardo ZN, Padilla G. Metabolic effects of calagualine, an antitumoral saponine of Polypodium leucotomos. Nature. 1967;214(5094):1256–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Murbach TS, Beres E, Vertesi A, Glavits R, Hirka G, Endres JR, et al. A comprehensive toxicological safety assessment of an aqueous extract of Polypodium leucotomos (Fernblock((R))). Food Chem Toxicol. 2015;86:328–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Nestor MS, Berman B, Swenson N. Safety and efficacy of oral Polypodium leucotomos extract in healthy adult subjects. J Clin Aesthet Dermatol. 2015;8(2):19–23.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Zattra E, Coleman C, Arad S, Helms E, Levine D, Bord E, et al. Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice. Am J Pathol. 2009;175(5):1952–61.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Alcaraz MV, Pathak MA, Rius F, Kollias N, Gonzalez S. An extract of Polypodium leucotomos appears to minimize certain photoaging changes in a hairless albino mouse animal model. A pilot study. Photodermatol Photoimmunol Photomed. 1999;15(3–4):120–6.Google Scholar
  26. 26.
    Gonzalez S, Pathak MA, Cuevas J, Villarrubia VG, Fitzpatrick TB. Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed. 1997;13(1–2):50–60.Google Scholar
  27. 27.
    Middelkamp-Hup MA, Pathak MA, Parrado C, Goukassian D, Rius-Diaz F, Mihm MC, et al. Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. 2004;51(6):910–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Villa A, Viera MH, Amini S, Huo R, Perez O, Ruiz P, et al. Decrease of ultraviolet A light-induced “common deletion” in healthy volunteers after oral Polypodium leucotomos extract supplement in a randomized clinical trial. J Am Acad Dermatol. 2010;62(3):511–3.CrossRefPubMedGoogle Scholar
  29. 29.
    Aguilera P, Carrera C, Puig-Butille JA, Badenas C, Lecha M, Gonzalez S, et al. Benefits of oral Polypodium Leucotomos extract in MM high-risk patients. J Eur Acad Dermatol Venereol. 2013;27(9):1095–100.CrossRefPubMedGoogle Scholar
  30. 30.
    Premi S, Wallisch S, Mano CM, Weiner AB, Bacchiocchi A, Wakamatsu K, et al. Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. Science (New York, NY). 2015;347(6224):842–7.Google Scholar
  31. 31.
    Hercberg S, Ezzedine K, Guinot C, Preziosi P, Galan P, Bertrais S, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr. 2007;137(9):2098–105.PubMedGoogle Scholar
  32. 32.
    Ezzedine K, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, et al. Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation. Eur J Cancer (Oxford, England : 1990). 2010;46(18):3316–22.Google Scholar
  33. 33.
    Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Philadelphia, Pa). 2012;5(2):164–78.Google Scholar
  34. 34.
    Ye X, Fu J, Yang Y, Gao Y, Liu L, Chen S. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS One. 2013;8(7):e71522.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology. 2005;68(1):40–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol. 2010;172(5):578–90.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Clouser MC, Roe DJ, Foote JA, Harris RB. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf. 2009;18(4):276–83.CrossRefPubMedGoogle Scholar
  38. 38.
    Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005;4(1):31–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Goodman JR, Grossman D. Aspirin and other NSAIDs as chemoprevention agents in melanoma. Cancer Prev Res (Philadelphia, Pa). 2014;7(6):557–64.Google Scholar
  40. 40.
    Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 2011;131(7):1460–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sorensen HT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer. 2012;118(19):4768–76.CrossRefPubMedGoogle Scholar
  42. 42.
    Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer. 2011;105(3):452–9.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women’s Health Initiative. Cancer. 2013;119(8):1562–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses’ Health Study. Cancer Causes Control. 2012;23(9):1451–61.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55.CrossRefPubMedGoogle Scholar
  46. 46.
    Curiel-Lewandrowski C, Swetter SM, Einspahr JG, Hsu CH, Nagle R, Sagerman P, et al. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer. 2012;118(23):5848–56.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer. 2007;110(11):2519–27.CrossRefPubMedGoogle Scholar
  48. 48.
    Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388–94.CrossRefPubMedGoogle Scholar
  49. 49.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22.CrossRefPubMedGoogle Scholar
  50. 50.
    Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst. 2006;98(21):1538–46.CrossRefPubMedGoogle Scholar
  51. 51.
    Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, et al. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prev Res (Phila). 2014;7(5):496–504.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Kligman LH, Akin FJ, Kligman AM. Sunscreens prevent ultraviolet photocarcinogenesis. J Am Acad Dermatol. 1980;3(1):30–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Noonan FP, Recio JA, Takayama H, Duray P, Anver MR, Rush WL, et al. Neonatal sunburn and melanoma in mice. Nature. 2001;413(6853):271–2.CrossRefPubMedGoogle Scholar
  54. 54.
    Drolet BA, Connor MJ. Sunscreens and the prevention of ultraviolet radiation-induced skin cancer. J Dermatol Surg Oncol. 1992;18(7):571–6.CrossRefPubMedGoogle Scholar
  55. 55.
    Hersey P, MacDonald M, Burns C, Schibeci S, Matthews H, Wilkinson FJ. Analysis of the effect of a sunscreen agent on the suppression of natural killer cell activity induced in human subjects by radiation from solarium lamps. J Invest Dermatol. 1987;88(3):271–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257–63.CrossRefPubMedGoogle Scholar
  57. 57.
    Carrera C, Puig-Butille JA, Aguilera P, Ogbah Z, Palou J, Lecha M, et al. Impact of sunscreens on preventing UVR-induced effects in nevi: in vivo study comparing protection using a physical barrier vs sunscreen. JAMA Dermatol. 2013;149(7):803–13.CrossRefPubMedGoogle Scholar
  58. 58.
    Michalopoulos P, Yawalkar N, Bronnimann M, Kappeler A, Braathen LR. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004;151(4):903–6.CrossRefPubMedGoogle Scholar
  59. 59.
    Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC. Treatment of dysplastic nevi with 5 % imiquimod cream, a pilot study. J Drugs Dermatol. 2006;5(1):56–62.PubMedGoogle Scholar
  60. 60.
    Somani N, Martinka M, Crawford RI, Dutz JP, Rivers JK. Treatment of atypical nevi with imiquimod 5 % cream. Arch Dermatol. 2007;143(3):379–85.CrossRefPubMedGoogle Scholar
  61. 61.
    Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527(7577):186–91.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Jagtap D, Rosenberg CA, Martin LW, Pettinger M, Khandekar J, Lane D, et al. Prospective analysis of association between use of statins and melanoma risk in the Women’s Health Initiative. Cancer. 2012;118(20):5124–31.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland (Outside the USA) 2016

Authors and Affiliations

  • Jessica Mounessa
    • 1
    • 2
  • Talayesa Buntinx-Krieg
    • 3
  • Rosie Qin
    • 4
  • Cory A. Dunnick
    • 2
    • 5
  • Robert P. Dellavalle
    • 2
    • 5
  1. 1.Stony Brook University School of MedicineStony BrookUSA
  2. 2.Department of DermatologyUniversity of Colorado HospitalAuroraUSA
  3. 3.University of Central Florida College of MedicineOrlandoUSA
  4. 4.Department of MedicineUniversity of San DiegoLa JollaUSA
  5. 5.Department of DermatologyDenver VA Medical CenterDenverUSA

Personalised recommendations